These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39426632)
1. A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis. Martínez-Campreciós J; Aznar ML; Zacarias A; Terán R; Nindia A; Espinosa-Pereiro J; Aixut S; Ramos ME; Nicolau MJ; Sulleiro E; Tórtola MT; Sánchez-Montalvá A; Molina I J Infect; 2024 Dec; 89(6):106291. PubMed ID: 39426632 [TBL] [Abstract][Full Text] [Related]
2. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China. Song Y; Shu W; Pei Y; Du J; Wu G; Wang H; Mi F; Liu F; Ma L; Xie L; Kong Z; Wu X; Liu R; Chen H; Li H; Ge Q; Nie L; Lv Z; Huang X; Li M; Jiang M; Chen X; Cai Q; Chen W; Liu Y; Miao Y; Tang Y; Chen Y; Geng S; Zhou Q; Liu Y; Pang Y; Gao M BMC Med; 2024 Sep; 22(1):401. PubMed ID: 39300460 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Goodall RL; Nunn AJ; Meredith SK; Bayissa A; Bhatnagar AK; Chiang CY; Conradie F; Gopalan N; Gurumurthy M; Kirenga B; Kiria N; Meressa D; Moodliar R; Ngubane N; Rassool M; Sanders K; Solanki R; Squire SB; Teferi M; Torrea G; Tsogt B; Tudor E; Van Deun A; Rusen ID; Lancet Respir Med; 2024 Dec; 12(12):975-987. PubMed ID: 39366400 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A Lancet Infect Dis; 2024 Oct; 24(10):1151-1161. PubMed ID: 38880112 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Padmapriyadarsini C; Oswal VS; Jain CD; Mariappan MV; Singla N; Kumar S; Daniel BD; Dave JD; Vadgama P; Ramraj B; Kant S; Bhatnagar AK; Shanmugam S; Paul D; Bharathi J; Palav M; Shah NV; Santhanakrishnan R; Dewan RK; Shekh N; Rathinam P; Sisara AB; Mankar SD; Bajpai J; Mittal U; Chauhan S; Kumar R; Parmar M; Mattoo SK; Jaju J; Clin Infect Dis; 2024 Dec; 79(6):1375-1385. PubMed ID: 39194339 [TBL] [Abstract][Full Text] [Related]
7. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND; Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Combined Bedaquiline and Delamanid Use among Patients with Multidrug-Resistant Tuberculosis in Beijing, China. Guo C; Nie L; Song Y; Liu R; Wu X; Shang Y; Zhang X; Pang Y; Gao M Biomed Environ Sci; 2024 Oct; 37(10):1195-1203. PubMed ID: 39622668 [TBL] [Abstract][Full Text] [Related]
9. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
10. Treatment success and mortality among people with multi-drug resistant and rifampicin resistant-tuberculosis on bedaquiline-based regimen at three referral hospitals in Uganda: A retrospective analysis. Jackson Dumo Lodiong L; Izudi J; Amanee Elias Lumori B J Clin Tuberc Other Mycobact Dis; 2024 Dec; 37():100499. PubMed ID: 39655087 [TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial. Dawson R; Diacon AH; De Jager V; Narunsky K; Moodley VM; Stinson KW; Liu Y; Zheng B; Hafkin J Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39612928 [TBL] [Abstract][Full Text] [Related]
12. Frameshift mutations in the Snobre J; Meehan CJ; Mulders W; Rigouts L; Buyl R; de Jong BC; Van Rie A; Tzfadia O Antimicrob Agents Chemother; 2024 Dec; 68(12):e0085424. PubMed ID: 39445816 [TBL] [Abstract][Full Text] [Related]
13. Diabetes as a risk factor for tuberculosis disease. Franco JV; Bongaerts B; Metzendorf MI; Risso A; Guo Y; Peña Silva L; Boeckmann M; Schlesinger S; Damen JA; Richter B; Baddeley A; Bastard M; Carlqvist A; Garcia-Casal MN; Hemmingsen B; Mavhunga F; Manne-Goehler J; Viney K Cochrane Database Syst Rev; 2024 Aug; 8(8):CD016013. PubMed ID: 39177079 [TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan. Rashitov M; Franke MF; Trevisi L; Bekbolatova G; Shalimova J; Eshmetov G; Bektasov S; LaHood A; Arlyapova N; Osso E; Yedilbayev A; Korotych O; Ciobanu A; Skrahina A; Mitnick CD; Seung KJ; Algozhin Y; Rich ML Clin Infect Dis; 2024 Oct; 79(4):1046-1053. PubMed ID: 38833593 [TBL] [Abstract][Full Text] [Related]
15. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen for adults with hepatocellular carcinoma. Naing C; Ni H; Aung HH Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750 [TBL] [Abstract][Full Text] [Related]
19. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation. Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138 [TBL] [Abstract][Full Text] [Related]